Kiora Pharmaceuticals, Inc.
KPRXNASDAQHealthcare● Active
$2.58
+$0.08(+3.20%)
Market Cap$11434405
P/E Ratio—
52W High$3.39
52W Low$1.765
Kiora Pharmaceuticals, Inc. (KPRX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
KPRX · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 8, 2026EPS Actual
-$0.58
Est. -$0.71 · +18.3%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 8, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
KPRX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 7, 2026 | -$0.47 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 8, 2026 | -$0.71 | -$0.58 | +18.3% | — | $0.00B | — |
| ▼ Q1 FY2026 | Mar 25, 2026 | -$0.67 | -$1.60 | -138.8% | — | $0.00B | — |
| ▲ Q4 FY2025 | Nov 7, 2025 | -$0.72 | $0.01 | +101.4% | — | $0.00B | — |
| ▲ Q3 FY2025 | Aug 8, 2025 | -$0.58 | -$0.54 | +6.9% | — | $0.00B | — |
| ▲ Q2 FY2025 | May 9, 2025 | -$0.77 | -$0.52 | +32.5% | — | $0.00B | — |
| ▼ Q1 FY2025 | Mar 25, 2025 | -$0.64 | -$1.04 | -62.5% | — | $0.00B | — |
| ▲ Q4 FY2024 | Nov 8, 2024 | -$0.90 | -$0.81 | +10.0% | — | $0.00B | — |
Q3 FY2026
Aug 7, 2026
EPS Actual
—
EPS Est.
-$0.47
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 8, 2026Beat
EPS Actual
-$0.58
EPS Est.
-$0.71
EPS Surpr.
+18.3%
Revenue
—
Q1 FY2026
Mar 25, 2026Miss
EPS Actual
-$1.60
EPS Est.
-$0.67
EPS Surpr.
-138.8%
Revenue
—
Q4 FY2025
Nov 7, 2025Beat
EPS Actual
$0.01
EPS Est.
-$0.72
EPS Surpr.
+101.4%
Revenue
—
Q3 FY2025
Aug 8, 2025Beat
EPS Actual
-$0.54
EPS Est.
-$0.58
EPS Surpr.
+6.9%
Revenue
—
Q2 FY2025
May 9, 2025Beat
EPS Actual
-$0.52
EPS Est.
-$0.77
EPS Surpr.
+32.5%
Revenue
—
Q1 FY2025
Mar 25, 2025Miss
EPS Actual
-$1.04
EPS Est.
-$0.64
EPS Surpr.
-62.5%
Revenue
—
Q4 FY2024
Nov 8, 2024Beat
EPS Actual
-$0.81
EPS Est.
-$0.90
EPS Surpr.
+10.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.30 | $-0.30 | $-0.30 | 1 |
| Q3 FY2027 | $-0.29 | $-0.29 | $-0.29 | 1 |
| Q2 FY2027 | $-0.27 | $-0.27 | $-0.27 | 1 |
| Q1 FY2027 | $-0.26 | $-0.26 | $-0.26 | 1 |
| Q4 FY2026 | $-0.25 | $-0.25 | $-0.25 | 1 |
| Q3 FY2026 | $-0.52 | $-0.52 | $-0.52 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 8, 2026 | +18.3% | $2.45 | $2.45 | +0.00% |
| ▼ Q1 FY2026 | Mar 25, 2026 | -138.8% | $2.06 | $2.04 | -0.97% |
| ▲ Q4 FY2025 | Nov 7, 2025 | +101.4% | $2.32 | $2.33 | +0.43% |
| ▲ Q3 FY2025 | Aug 8, 2025 | +6.9% | $2.39 | $2.36 | -1.26% |
| ▲ Q2 FY2025 | May 9, 2025 | +32.5% | $3.12 | $3.25 | +4.17% |
| ▼ Q1 FY2025 | Mar 25, 2025 | -62.5% | $3.20 | $3.04 | -5.00% |
| ▲ Q4 FY2024 | Nov 8, 2024 | +10.0% | $3.57 | $3.53 | -1.12% |
| ▲ Q3 FY2024 | Aug 9, 2024 | +44.2% | $3.26 | $3.35 | +2.76% |
Q2 FY2026+0.00%
Report Date
May 8, 2026
EPS Beat/Miss
+18.3%
Price Before
$2.45
Price After
$2.45
Q1 FY2026-0.97%
Report Date
Mar 25, 2026
EPS Beat/Miss
-138.8%
Price Before
$2.06
Price After
$2.04
Q4 FY2025+0.43%
Report Date
Nov 7, 2025
EPS Beat/Miss
+101.4%
Price Before
$2.32
Price After
$2.33
Q3 FY2025-1.26%
Report Date
Aug 8, 2025
EPS Beat/Miss
+6.9%
Price Before
$2.39
Price After
$2.36
Q2 FY2025+4.17%
Report Date
May 9, 2025
EPS Beat/Miss
+32.5%
Price Before
$3.12
Price After
$3.25
Q1 FY2025-5.00%
Report Date
Mar 25, 2025
EPS Beat/Miss
-62.5%
Price Before
$3.20
Price After
$3.04
Q4 FY2024-1.12%
Report Date
Nov 8, 2024
EPS Beat/Miss
+10.0%
Price Before
$3.57
Price After
$3.53
Q3 FY2024+2.76%
Report Date
Aug 9, 2024
EPS Beat/Miss
+44.2%
Price Before
$3.26
Price After
$3.35
Avg Beat Reaction+0.83%
Avg Miss Reaction-2.98%
Beat Rate6 / 8 quarters
Largest Move-5.00% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: KPRX ends December
Kiora Pharmaceuticals, Inc. (KPRX) most recently reported earnings on May 8, 2026 for Q2 FY2026, posting EPS of $-0.58 — beating the analyst consensus of $-0.71 by +18.3%. The next KPRX earnings date is expected around September 1, 2026.
Each quarter, investors track KPRX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. KPRX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
KPRX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
KPRX earnings · 5 questionsKiora Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. KPRX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; KPRX historically reports after market close (AMC).
KPRX earnings datewhen is KPRX earningsKPRX next earnings datewhen does KPRX report earningsKPRX earnings calendar
▸ Source: FMP · Kiora Pharmaceuticals, Inc. SEC filings · US GAAP · Kiora Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026